Skip to main content

Xavier Montalban Gairín

I am director of the Multiple Sclerosis Center of Catalonia (Cemcat) at Vall d'Hebron University Hospital since 2007 and Head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Universitat Autònoma de Barcelona (UAB) since 2006 and at Universitat de Vic – Universitat Central de Catalunya (UVic-UCC) since 2021. Additionally, I serve as Senior Consultant in the Department of Neurology at Vall d'Hebron University Hospital.

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Xavier Montalban Gairín

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am director of the Multiple Sclerosis Center of Catalonia (Cemcat) at Vall d'Hebron University Hospital since 2007 and Head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Universitat Autònoma de Barcelona (UAB) since 2006 and at Universitat de Vic – Universitat Central de Catalunya (UVic-UCC) since 2021. Additionally, I serve as Senior Consultant in the Department of Neurology at Vall d'Hebron University Hospital.

I obtained my MD (1983) and PhD (1990) from UAB, specializing in Neurology at Vall d'Hebron University Hospital (1988) and completing my postdoctoral fellowship at St Thomas’ Hospital and the National Hospital for Neurology and Neurosurgery (London). I earned a Diploma in Comprehensive Healthcare Institutions Management from ESADE (2005).

From 2012 to December 2024, I served as Chair of the Neurology Department at Vall d’Hebron University Hospital. Between 2017 and 2020, I was Professor of Medicine and Director of the Division of Neurology at the University of Toronto, as well as Director of the MS Center at St Michael’s Hospital, Toronto.

I am past President (2014-2016) and current Honorary Member of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). I also served as Co-Chair of the Steering Committee of Magnetic Imaging in Multiple Sclerosis (MAGNIMS) and a member of the Steering Committee of the International Progressive MS Alliance. Since December 2024, I have been Vice President of the European Charcot Foundation. Additionally, I chaired the International Advisory Committee on Clinical Trials in MS, sponsored by ECTRIMS and the National Multiple Sclerosis Society (NMSS), until December 2024.

My scientific output includes over 800 peer-reviewed publications, with more than 65,000 citations and a Scopus H-Index of 110 (January 2025). Over the last seven years, I have been among Clarivate’s most cited researchers. I have been Principal Investigator (PI) or collaborator in over 35 competitive projects (€8.5 million) and more than 150 clinical trials.

Notably, I received the 2022 John Dystel Prize (AAN and NMSS), the 2023 Charcot Award (MSIF) for lifetime achievements in MS research, the 2024 Fundación Lilly Award for Biomedical Research, and the 2023 ICS Career Research Award for clinical and scientific excellence.

Projects

Función de las proteínas de choque técnico (HSP, heat shock protein)-70 en la patogenia de la esclerosis múltiple

IP: Xavier Montalban Gairín
Collaborators: Carmen Espejo Ruiz, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 109804.5
Reference: MS07/00146
Duration: 01/01/2008 - 31/12/2013

REEM - Red Española de Esclerosis Múltiple

IP: Xavier Montalban Gairín
Collaborators: Carlos Nos Llopis, Sunny Malhotra Sareen, Jaume Sastre Garriga, Jordi Rio Izquierdo, Fco. Javier Aymerich Martínez, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Alex Rovira Cañellas, Mar Tintore Subirana, M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo
Funding agency: Instituto de Salud Carlos III
Funding: 364373.77
Reference: RD07/0060/0020
Duration: 01/01/2008 - 31/12/2014

Espectroscopia por RM de protón e imagen de transferencia de magnetización en el estudio de primeros episodios sugestivos de Esclerosis Múltiple.

IP: -
Collaborators: Alex Rovira Cañellas, Mar Tintore Subirana, Xavier Montalban Gairín
Funding agency: Instituto de Salud Carlos III
Funding: 40940
Reference: PI020971
Duration: 06/11/2002 - 31/12/2005

Estudio de la Heterogeneidad de la Esclerosis Múltiple Remitente-Recurrente Mediante Resonancia Magnética y Perfiles de Expresión Génica

IP: Xavier Montalban Gairín
Collaborators: Jordi Rio Izquierdo, Alex Rovira Cañellas
Funding agency: Instituto de Salud Carlos III
Funding: 150040
Reference: PI061334
Duration: 01/01/2007 - 30/06/2010

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Francisco Javier Carvajal Rodriguez

Francisco Javier Carvajal Rodriguez

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Margot Noemi Costa Gutiérrez

Margot Noemi Costa Gutiérrez

Administrative
General Services and Infrastructures Unit
Manager
Read more
Judit Vico Romero

Judit Vico Romero

Research technician
Liver Diseases
Read more
Sandra Torres Sierra

Sandra Torres Sierra

Research technician
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.